Senescent Cell Biomarkers for High-Specificity Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current biomarkers for senescent cells are not specific or sensitive enough, leading to difficulties in accurately identifying and targeting these cells, which are associated with aging and tumorigenesis.

Innovation Solution

Identification of ten novel specific markers of senescence, including DEP-1, NTAL, EBP50, STX4, VAMP3, ARMCX-3, LANCL1, B2MG, PLD3, and VPS26A, which are associated with the plasma membrane of senescent cells and can be used to develop more effective detection and targeting methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional biomarkers (such as SA-β-Gal) are used to detect senescent cells, then detection can be performed, but the specificity and sensitivity are insufficient leading to false positives

Engineering Contradiction:

Improvedetection accuracyVSAvoidmarker specificity

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent divides the detection task into multiple independent marker assessments rather than relying on a single biomarker. By evaluating multiple plasma membrane proteins simultaneously, the system segments the detection process to achieve higher overall accuracy and reduce false positives from individual markers

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the detection parameters by identifying and measuring multiple different protein markers (DEP-1, NTAL, EBP50, STX4, VAMP3, ARMCX-3, LANCL1, B2MG, PLD3, VPS26A) instead of using a single parameter. This multi-parameter approach transforms the detection system to achieve both high sensitivity and specificity

Inventive Principle:

Principle #35Parameter changes

2Productivity

If existing markers are used, then senescent cells can be identified, but the identification is not conclusive or satisfactory

Engineering Contradiction:

Improvedetection efficiencyVSAvoididentification accuracy

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent creates a composite detection system by combining multiple plasma membrane protein markers into a unified detection approach. This composite strategy integrates information from various markers to achieve conclusive identification of senescent cells, overcoming the limitations of individual markers

Inventive Principle:

Principle #40Composite materials

3Measurement precision

If more markers are identified, then detection sensitivity improves, but the complexity of the detection system increases

Engineering Contradiction:

Improvedetection sensitivityVSAvoidmarker profile complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies universality by developing a detection system that uses multiple markers with different functions and characteristics. Each marker contributes uniquely to senescent cell detection, and the system is designed to evaluate all markers through a unified methodology, achieving high sensitivity without proportionally increasing operational complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12313631B2Senescent cell biomarkers

Publication Date: 2025.05.27 UNIVERSITY OF LEICESTER

AI summary

The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.